| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
|
Purity: ≥98%
| Targets |
β-lactam
|
|---|---|
| ln Vitro |
At ATCC 25923 and E19977, dicloxacillin displays EC50 values of 0.06 and 0.50 mg/L, respectively. In ATCC 25923 and E19977, dicloxacillin displays minimum inhibitory concentrations (MIC) of 0.125 and 0.5 mg/L at pH 7.4 respectively[3].
|
| ln Vivo |
When used in a murine peritonitis-sepsis model, dicloxacillin shows therapeutic activity, and all of the mice survive1–4.
|
| Cell Assay |
Cell Line: Strains ATCC 25923 and E19977.
Concentration: 0-500 mg/L. Incubation Time: Up to 24 h. Result: EC50 values in ATCC 25923 and E19977 were found to be 0.06 and 0.50 mg/L, respectively. |
| Animal Protocol |
Animal Model: Female outbred Swiss Webster mice (Murine peritonitis-sepsis model)[4].
Dosage: 125 mg/kg. Administration: IV injection, single doses. Result: All the mice survived. |
| References |
|
| Molecular Formula |
C19H17N3O5SCL2.NA+
|
|---|---|
| Molecular Weight |
493.31618
|
| Elemental Analysis |
C, 44.72; H, 3.56; Cl, 13.89; N, 8.23; Na, 4.50; O, 18.81; S, 6.28
|
| CAS # |
13412-64-1
|
| Related CAS # |
Dicloxacillin sodium;343-55-5;Dicloxacillin;3116-76-5
|
| Appearance |
Solid powder
|
| SMILES |
O=C([C@@H](C(C)(C)S[C@]1([H])[C@@H]2NC(C3=C(C)ON=C3C4=C(Cl)C=CC=C4Cl)=O)N1C2=O)[O-].[H]O[H].[Na+]
|
| InChi Key |
SIGZQNJITOWQEF-VICXVTCVSA-M
|
| InChi Code |
InChI=1S/C19H17Cl2N3O5S.Na.H2O/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24;;/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28);;1H2/q;+1;/p-1/t13-,14+,17-;;/m1../s1
|
| Chemical Name |
sodium (2S,5R,6R)-6-(3-(2,6-dichlorophenyl)-5-methylisoxazole-4-carboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate hydrate
|
| Synonyms |
Dicloxacillin sodium hydrate; BLP-1011; BRL-1702; P 1011; P-1011; P1011; MDI-PC
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL ( ~195.95 mM )
Water : 25~100 mg/mL(~48.99 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 25 mg/mL (48.99 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0271 mL | 10.1354 mL | 20.2708 mL | |
| 5 mM | 0.4054 mL | 2.0271 mL | 4.0542 mL | |
| 10 mM | 0.2027 mL | 1.0135 mL | 2.0271 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05073627 | COMPLETED | Drug: Dicloxacillin | Drug-drug Interaction Healthy Volunteers |
University of Southern Denmark | 2022-02-07 | Phase 1 |
| NCT05578482 | RECRUITING | Drug: Dicloxacillin Oral Capsule Drug: Elocon 0.1 % Topical Cream |
Atopic Dermatitis Atopic Dermatitis Eczema Atopic Dermatitis Flare |
Jacob Pontoppidan Thyssen | 2022-10-24 | Phase 4 |
| NCT02983890 | COMPLETED | Drug: Dicloxacillin Drug: Placebos |
Healthy | Per Damkier | 2016-10-06 | Phase 1 |
| NCT00037050 | COMPLETED | Drug: Linezolid Drug: Vancomycin Drug: Oxacillin Drug: Dicloxacillin |
Bacteremia Bacterial Infections Gram-Positive Bacterial Infections |
Pfizer | 2002-04 | Phase 3 |
| NCT04563325 | ACTIVE, NOT RECRUITING | Drug: Oral co-amoxiclav or oral dicloxacillin only Drug: IV ceftriaxon followed by oral co-amoxiclav or oral dicloxacillin |
Bone Infection Bone and Joint Infection Joint Infection Osteomyelitis Septic Arthritis |
Rigshospitalet, Denmark | 2020-09-15 | Phase 4 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA